Plain-English translation of NCT06869213 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called adebrelimab (SHR-1316) combined with standard chemotherapy drugs to treat advanced esophageal cancer that can be removed by surgery. The study will give patients the medication and chemotherapy before surgery to try to shrink the tumor, then the medication alone after surgery to help prevent cancer from coming back. The goal is to see if adding this immune-boosting treatment improves outcomes for people with this type of cancer.
Advanced esophageal cancer is a serious disease, and while surgery is important, cancer often returns or spreads despite treatment. This medication works by helping your immune system fight cancer cells more effectively, and researchers want to see if combining it with chemotherapy during the period around surgery can improve survival and keep cancer from returning.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive the new medication along with two chemotherapy drugs as infusions before surgery to help shrink your tumor. After your surgery to remove the cancer, you would then receive the medication alone for additional treatment. The study involves regular clinic visits for infusions and blood tests to monitor your health and how well the treatment is working. The entire treatment will take several months, and researchers will follow your progress closely to ensure the treatment is safe and effective.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China